{
    "nctId": "NCT00398489",
    "briefTitle": "Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery",
    "officialTitle": "Evaluation of Response Rate to Pre-Operative Docetaxel + Herceptin Study Part A and Docetaxel Study Part B in Locally Advanced Breast Cancer Patients, Stratified by HER2-Status Trial - PHASE II [(Herceptin Docetaxel Neoadjuvant) HEDON]",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "N/A",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 94,
    "primaryOutcomeMeasure": "Rate of pathologic complete remission (pCR) after neoadjuvant therapy comprising docetaxel and trastuzumab (Herceptin\u00ae) in women with locally advanced, HER2-positive, operable breast cancer",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed primary carcinoma of the breast by core biopsy\n* Solitaire or multifocal disease, defined as tumor manifestations within a quadrant or distance between tumor manifestations measured bilaterally \\< 4 cm, respectively\n\n  * No multifocal primary tumor, defined as tumor manifestations in different quadrants or distance between tumor manifestations \u2265 4 cm\n* Locally advanced, operable disease\n\n  * Primary tumor \u2265 2 cm by clinical examination or imaging (i.e., mammogram, MRI, or ultrasound)\n\n    * Inflammatory breast cancer with bidimensionally measurable lesion, independent of nodal status, allowed\n* HER2 status meeting 1 of the following criteria:\n\n  * HER2-positive disease\n\n    * 3+ by immunohistochemistry (IHC) and/or positive by fluorescence in situ hybridization (FISH)\n  * HER-2 negative disease\n\n    * 0 or 1+ by IHC OR 2+ by IHC and negative by FISH\n* No distant metastases by clinical or imaging diagnosis\n* No prior breast cancer\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* Female\n* Pre- or post-menopausal\n* ECOG performance status 0-2\n* Platelet count \u2265 100,000/mm\\^3\n* Neutrophil count \u2265 1,500/mm\\^3\n* Hemoglobin \u2265 10 g/dL\n* ALT and AST \u2264 1.5 times upper limit of normal (ULN)\n* Alkaline phosphatase \u2264 2.5 times ULN\n* Creatinine \u2264 1.5 times ULN\n* Bilirubin normal (unless due to clearly documented Gilbert's syndrome)\n* Not pregnant or nursing\n* Negative pregnancy test (for premenopausal women or women with a postmenopausal status for \\< 1 year)\n* Fertile patients must use effective contraception\n* Adequate organ function for cytotoxic chemotherapy\n* No known hypersensitivity reaction to the study agents or incorporated substances\n* No known allergy or severe reactions to trastuzumab or its constituents (for patients with HER2-positive disease)\n* No preexisting motor or sensory neuropathy \u2265 grade 2\n* No other invasive malignancy within the past 5 years that would preclude study compliance or affect the interpretation of study results\n* LVEF \u2265 55% by MUGA or echocardiography\n* No other serious illness or medical condition, including any of the following:\n\n  * New York Heart Association class II-IV congestive heart failure\n  * History of documented congestive heart failure\n  * Unstable angina pectoris\n  * Myocardial infarction within the past 12 months\n  * Uncontrolled hypertension (i.e., systolic blood pressure \\[BP\\] \\> 180 mm Hg or diastolic BP \\> 100 mm Hg)\n  * Clinically significant valvular heart disease\n  * High-risk, uncontrolled arrhythmias\n  * Dyspnea at rest due to malignant or other disease\n  * Condition that requires supportive oxygen therapy\n  * Active serious uncontrolled infections\n  * Uncontrolled diabetes\n\nPRIOR CONCURRENT THERAPY:\n\n* No prior systemic therapy for cancer\n* No prior trastuzumab (Herceptin\\^\u00ae) (for HER2-positive patients)\n* No other concurrent anticancer therapy\n* No other concurrent investigational drugs\n* No concurrent immunosuppressive therapy\n* No concurrent sex hormones\n* No concurrent corticosteroids unless for premedication\n* No concurrent bisphosphonates during active treatment with chemotherapy",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}